PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21671107-8	2011	The study demonstrated that methadone and buprenorphine exert initially different yet eventually convergent adaptive changes of AC activity in cells coexpressing human MOR and ORL1 receptors.	Buprenorphine	42-55	opioid related nociceptin receptor 1	Homo sapiens	176-180	
10998549-2	2000	Recently, we have identified buprenorphine as a full ORL1 agonist using a reporter gene assay.	Buprenorphine	29-42	opioid related nociceptin receptor 1	Homo sapiens	53-57	
10998549-3	2000	For further functional analysis, buprenorphine"s effects on ORL1 receptors were investigated using a K(+) channel (GIRK1) assay in Xenopus oocytes and GTPgammaS assay in CHO-K1 membrane preparations.	Buprenorphine	33-46	opioid related nociceptin receptor 1	Homo sapiens	60-64	
10688973-8	2000	The nonselective opioid receptor partial agonist buprenorphine and the nonselective opioid receptor antagonist (-)-quadazocine exhibited pure antagonism at rat brain receptors, but displayed partial agonism at human ORL1 receptors.	Buprenorphine	49-62	opioid related nociceptin receptor 1	Homo sapiens	216-220	
33608331-5	2021	We describe a successful sustained rescue of a difficult 2-year-long PLP case with sublingual buprenorphine/naloxone using the drug"s potent multimodal mechanisms of action: potent long-acting mu agonist/antagonist, kapa receptor antagonist, delta receptor antagonist and novel opioid receptor-like 1 (OR-L1) agonist effects.	Buprenorphine	94-107	opioid related nociceptin receptor 1	Homo sapiens	278-300	
33608331-5	2021	We describe a successful sustained rescue of a difficult 2-year-long PLP case with sublingual buprenorphine/naloxone using the drug"s potent multimodal mechanisms of action: potent long-acting mu agonist/antagonist, kapa receptor antagonist, delta receptor antagonist and novel opioid receptor-like 1 (OR-L1) agonist effects.	Buprenorphine	94-107	opioid related nociceptin receptor 1	Homo sapiens	302-307	
22119647-1	2012	Buprenorphine (BUP) is a partial agonist at mu-, delta- and ORL1 (opioid receptor-like)/nociceptin receptors and antagonist at the kappa-opioid receptor site.	Buprenorphine	0-13	opioid related nociceptin receptor 1	Homo sapiens	44-87	
10419552-4	1999	Buprenorphine was identified as a full agonist at the ORL1 receptor with an IC(50) value of 8.4 +/- 2.8 nM.	Buprenorphine	0-13	opioid related nociceptin receptor 1	Homo sapiens	54-58	
29913911-6	2013	Results Buprenorphine is a potent opioid analgesic acting on all four opioid receptors: it is an agonist on the mu-, the delta, and the ORL-1 receptors.	Buprenorphine	8-21	opioid related nociceptin receptor 1	Homo sapiens	136-141	
20099319-3	2011	Despite the current clinical use of a morphinane-based NOP/MOP mixed ligand (buprenorphine) as an analgesic and in the treatment of drug addictions, so far just a few clinical trials have been made with selective NOP ligands.	Buprenorphine	77-90	opioid related nociceptin receptor 1	Homo sapiens	55-58	
20099319-3	2011	Despite the current clinical use of a morphinane-based NOP/MOP mixed ligand (buprenorphine) as an analgesic and in the treatment of drug addictions, so far just a few clinical trials have been made with selective NOP ligands.	Buprenorphine	77-90	opioid related nociceptin receptor 1	Homo sapiens	213-216